Systemic treatment options in advanced colorectal cancer: Perspectives on combination 5-fluorouracil plus leucovorin

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

A variety of 5-fluorouracil (5-PU)-based chemotherapy regimens have been investigated in colorectal cancer patients in randomized trials over the past decade. The standard regimen for treatment of colorectal cancer is combination 5-FU plus leucovorin (LV). The results from 12 randomized trials indicate that 5-FU/LV is more active than single-agent 5-FU (25% v 14% of evaluable patients); however, median survival was unchanged (12.2 months v 11.4 months, respectively). Furthermore, the weekly and monthly schedules of 5-FU/LV are therapeutically equivalent, although the spectrum of toxicity differs. On the monthly schedule, a LV dose of 200 mg/m2 appears to have no advantage over 20 mg/m2; however, on the weekly schedule, high-dose LV appeared to be slightly more effective than low-dose LV (2-hour infusion) (25% v 18%) at the cost of a higher incidence of severe diarrhea (26% v 14%). Furthermore, similar response rates are observed with the racemic commercial formulation of LV and the pure (I-LV) active stereoisomer. Other modulatory strategies that appear to produce higher response rates than single-agent intravenous push 5-PU include sequential methotrexate/5-FU (19% v 10%) and continuous infusion schedules (22% v 14%). Although 5-FU-modulated strategies improve response rates over those observed with single-agent 5-FU, median survival in multi-institutional trials unfortunately has not generally exceeded 12 months. The mechanism of action, clinical activity, and toxicity of single-agent 5-FU and 5-FU-modulated regimens are reviewed.

Original languageEnglish (US)
Pages (from-to)S18-8-S18-18
JournalSeminars in Oncology
Volume24
Issue number5 SUPPL. 18
StatePublished - Dec 1 1997

Fingerprint

Leucovorin
Fluorouracil
Colorectal Neoplasms
Appointments and Schedules
Therapeutics
Stereoisomerism
Survival
Methotrexate
Diarrhea
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Systemic treatment options in advanced colorectal cancer : Perspectives on combination 5-fluorouracil plus leucovorin. / Grem, J. L.

In: Seminars in Oncology, Vol. 24, No. 5 SUPPL. 18, 01.12.1997, p. S18-8-S18-18.

Research output: Contribution to journalReview article

@article{4542b9f5268a47788a836a69e9098ae5,
title = "Systemic treatment options in advanced colorectal cancer: Perspectives on combination 5-fluorouracil plus leucovorin",
abstract = "A variety of 5-fluorouracil (5-PU)-based chemotherapy regimens have been investigated in colorectal cancer patients in randomized trials over the past decade. The standard regimen for treatment of colorectal cancer is combination 5-FU plus leucovorin (LV). The results from 12 randomized trials indicate that 5-FU/LV is more active than single-agent 5-FU (25{\%} v 14{\%} of evaluable patients); however, median survival was unchanged (12.2 months v 11.4 months, respectively). Furthermore, the weekly and monthly schedules of 5-FU/LV are therapeutically equivalent, although the spectrum of toxicity differs. On the monthly schedule, a LV dose of 200 mg/m2 appears to have no advantage over 20 mg/m2; however, on the weekly schedule, high-dose LV appeared to be slightly more effective than low-dose LV (2-hour infusion) (25{\%} v 18{\%}) at the cost of a higher incidence of severe diarrhea (26{\%} v 14{\%}). Furthermore, similar response rates are observed with the racemic commercial formulation of LV and the pure (I-LV) active stereoisomer. Other modulatory strategies that appear to produce higher response rates than single-agent intravenous push 5-PU include sequential methotrexate/5-FU (19{\%} v 10{\%}) and continuous infusion schedules (22{\%} v 14{\%}). Although 5-FU-modulated strategies improve response rates over those observed with single-agent 5-FU, median survival in multi-institutional trials unfortunately has not generally exceeded 12 months. The mechanism of action, clinical activity, and toxicity of single-agent 5-FU and 5-FU-modulated regimens are reviewed.",
author = "Grem, {J. L.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "24",
pages = "S18--8--S18--18",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 18",

}

TY - JOUR

T1 - Systemic treatment options in advanced colorectal cancer

T2 - Perspectives on combination 5-fluorouracil plus leucovorin

AU - Grem, J. L.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - A variety of 5-fluorouracil (5-PU)-based chemotherapy regimens have been investigated in colorectal cancer patients in randomized trials over the past decade. The standard regimen for treatment of colorectal cancer is combination 5-FU plus leucovorin (LV). The results from 12 randomized trials indicate that 5-FU/LV is more active than single-agent 5-FU (25% v 14% of evaluable patients); however, median survival was unchanged (12.2 months v 11.4 months, respectively). Furthermore, the weekly and monthly schedules of 5-FU/LV are therapeutically equivalent, although the spectrum of toxicity differs. On the monthly schedule, a LV dose of 200 mg/m2 appears to have no advantage over 20 mg/m2; however, on the weekly schedule, high-dose LV appeared to be slightly more effective than low-dose LV (2-hour infusion) (25% v 18%) at the cost of a higher incidence of severe diarrhea (26% v 14%). Furthermore, similar response rates are observed with the racemic commercial formulation of LV and the pure (I-LV) active stereoisomer. Other modulatory strategies that appear to produce higher response rates than single-agent intravenous push 5-PU include sequential methotrexate/5-FU (19% v 10%) and continuous infusion schedules (22% v 14%). Although 5-FU-modulated strategies improve response rates over those observed with single-agent 5-FU, median survival in multi-institutional trials unfortunately has not generally exceeded 12 months. The mechanism of action, clinical activity, and toxicity of single-agent 5-FU and 5-FU-modulated regimens are reviewed.

AB - A variety of 5-fluorouracil (5-PU)-based chemotherapy regimens have been investigated in colorectal cancer patients in randomized trials over the past decade. The standard regimen for treatment of colorectal cancer is combination 5-FU plus leucovorin (LV). The results from 12 randomized trials indicate that 5-FU/LV is more active than single-agent 5-FU (25% v 14% of evaluable patients); however, median survival was unchanged (12.2 months v 11.4 months, respectively). Furthermore, the weekly and monthly schedules of 5-FU/LV are therapeutically equivalent, although the spectrum of toxicity differs. On the monthly schedule, a LV dose of 200 mg/m2 appears to have no advantage over 20 mg/m2; however, on the weekly schedule, high-dose LV appeared to be slightly more effective than low-dose LV (2-hour infusion) (25% v 18%) at the cost of a higher incidence of severe diarrhea (26% v 14%). Furthermore, similar response rates are observed with the racemic commercial formulation of LV and the pure (I-LV) active stereoisomer. Other modulatory strategies that appear to produce higher response rates than single-agent intravenous push 5-PU include sequential methotrexate/5-FU (19% v 10%) and continuous infusion schedules (22% v 14%). Although 5-FU-modulated strategies improve response rates over those observed with single-agent 5-FU, median survival in multi-institutional trials unfortunately has not generally exceeded 12 months. The mechanism of action, clinical activity, and toxicity of single-agent 5-FU and 5-FU-modulated regimens are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0031471150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031471150&partnerID=8YFLogxK

M3 - Review article

C2 - 9420016

AN - SCOPUS:0031471150

VL - 24

SP - S18-8-S18-18

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 18

ER -